The association between primary hyperparathyroidism and malignancy: nationwide cohort analysis on cancer incidence after parathyroidectomy.

In order to evaluate the link between primary hyperparathyroidism (pHPT) and malignancies, cases subjected to parathyroid adenomectomy (PTX) during 1958-1997 in Sweden were identified by analyzing the National Swedish Cancer Registry. To minimize the influence of confounding by detection, cases with malignant disease diagnosed before or at the same time as pHPT or during the first year after PTX were excluded. Altogether 9782 cases (7642 female) were included and followed for up to 40 years. Thus, the study comprises 89,571 person-years of observation. The incidence of malignancies was compared with that in the Swedish population standardized for age, sex, and calendar year. An increased overall incidence of cancer was demonstrated in both genders (standardized incidence ratio (SIR) 1.43, 95% confidence interval (CI) 1.35-1.52). This remain unchanged beyond 15 years after PTX. Breast cancer contributed a quarter of the cancer incidence in women (SIR 1.44, 95% CI 1.25-1.62). An increased risk of kidney (SIR 2.40, 95% CI 1.72-3.25), colonic (SIR 1.46, 95% CI 1.19-1.77), and squamous cell skin cancer (SIR 2.79, 95% CI 2.25-3.43) was found in both genders. The risk of endocrine and pancreas cancer was increased in the minority of patients who had their PTX before the age of 40. We conclude that pHPT is associated with an increased risk of developing malignancies that persists even after PTX. This suggests a causal disassociation with the biochemical derangements caused by parathyroid adenoma, while potentially common etiological mechanisms may include genetic predisposition or acquired disability to withstand environmental influence.

[1]  J. Rastad,et al.  Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population‐based study over five years , 2002, Clinical endocrinology.

[2]  K. Michels,et al.  Hyperparathyroidism and subsequent incidence of breast cancer , 2004, International journal of cancer.

[3]  P. Hall,et al.  Parathyroid adenoma and primary CNS tumors , 2005, International journal of cancer.

[4]  D. Bikle,et al.  Vitamin D and skin cancer: A problem in gene regulation , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  C. Marcocci,et al.  Increased prevalence of primary hyperparathyroidism in treated breast cancer , 2001, Journal of endocrinological investigation.

[6]  N. Samaan,et al.  Hypercalcemia in patients with known malignent disease. , 1976, Surgery.

[7]  L. Brinton,et al.  Hyperparathyroidism and subsequent cancer risk in Denmark , 2002, Cancer.

[8]  S. Massry,et al.  Primary hyperparathyroidism in patients with breast carcinoma. , 1970, Archives of surgery.

[9]  A. Odén,et al.  Recurrence of hyperparathyroidism; a long-term follow-up after surgery for primary hyperparathyroidism. , 2003, European Journal of Endocrinology.

[10]  J. Carpten,et al.  Hyperparathyroidism‐jaw tumour syndrome , 2003, Journal of internal medicine.

[11]  I. Reid,et al.  Association between primary hyperparathyroidism and increased body weight: a meta-analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[12]  J. Rastad,et al.  Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. , 2000, The Journal of clinical endocrinology and metabolism.

[13]  K. Emerson Endocrinology and metabolism. , 1952, Medicine of the year.

[14]  L. Melton,et al.  Survival after the diagnosis of hyperparathyroidism: a population-based study. , 1998, The American journal of medicine.

[15]  J. Rastad,et al.  Mortality in sporadic primary hyperparathyroidism: nationwide cohort study of multiple parathyroid gland disease. , 2004, Surgery.

[16]  J. Rastad,et al.  Vitamin D receptor (VDR) and parathyroid hormone messenger ribonucleic acid levels correspond to polymorphic VDR alleles in human parathyroid tumors. , 1998, The Journal of clinical endocrinology and metabolism.

[17]  B Mattsson,et al.  Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. , 1984, Acta radiologica. Oncology.

[18]  Edward Giovannucci,et al.  The epidemiology of vitamin D and cancer incidence and mortality: A review (United States) , 2005, Cancer Causes & Control.

[19]  N. E. Breslow Statistical Methods in Cancer Research , 1986 .

[20]  B. Bengtsson,et al.  Premature death in patients operated on for primary hyperparathyroidism , 1990, World Journal of Surgery.

[21]  P. Lindblom,et al.  Preoperative Normal Level of Parathyroid Hormone Signifies an Early and Mild Form of Primary Hyperparathyroidism , 2003, World Journal of Surgery.

[22]  H. Adami,et al.  Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study. , 1988, American journal of epidemiology.

[23]  E. Thurfjell,et al.  Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. , 1997, Surgery.

[24]  A. Odén,et al.  Parathyroid adenoma weight and the risk of death after treatment for primary hyperparathyroidism. , 1995, Surgery.

[25]  A. Vortmeyer,et al.  Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma , 2001, Oncogene.

[26]  G. Åkerström,et al.  Patients with primary hyperparathyroidism operated on over a 24-year period: temporal trends of clinical and laboratory findings. , 1987, Journal of chronic diseases.

[27]  S. Valdemarsson,et al.  Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease , 1998, Journal of internal medicine.

[28]  Harri Vainio,et al.  Overweight, obesity, and cancer risk. , 2002, The Lancet. Oncology.

[29]  J. Söreide,et al.  Survival after surgical treatment for primary hyperparathyroidism. , 1997, Surgery.